DOI:
https://doi.org/10.20882/adicciones.224Palabras clave:
Resumen
Citas
United Nations Office on Drugs and Crime. World Drug Report 2005. Vienna: United Nations; 2005.
McCaughan J, Carlson R, Falck R, Siegal H. From “Candy Kids” to
“Chemi-kids”: a typology of young adults who attend raves in the midwestern United States. Subst Use Misuse 2005;40:1503-23.
Topp L, Hando J, Dillon P, Roche A, Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999;55:105-15.
Ter Bogt T, Engels R. ‘Partying’ hard: party style, motives for and effects of MDMA use at rave parties. Subst Use Misuse 2005;40:1479-502.
Scholey A, Parrott A, Buchanan T, Heffernan T, Ling J, Rodgers B.
Increased intensity of ecstasy and polydrug usage in the more experienced recreational ecstasy/MDMA users: A WWW study.Addict Behav 2004;29:743-52.
Tossmann P, Boldt S, Tensil M. The use of drugs within the techno party scene in European Metropolitan cities. Eur Addict Res 2001;7(1):2-23.
Winstock A, Griffiths P, Stewart D. Drugs and the dance music scene: A survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 2001;64:9-17.
Kurtz S, Inciardi J, Surratt H, Cottler L. Prescription drug abuse among ecstasy users in Miami. J Addict Dis 2005;24(4):1-16.
Black E, Dunn M, Degenhardt L, Campbell G, George J, Kinner S, et al. Australian trends in ecstasy and related drug markets 2007: Findings from the Ecstasy and Related Drugs Reporting System (EDRS). Australian Drug Trends Series No. 10. Sydney: National Drug and Alcohol Research Centre; University of New South Wales; 2008.
McCambridge J, Mitcheson L, Hunt N, Winstock A. The rise of Viagra among British illicit drug users: 5-year survey data. Drug Alcohol Rev 2006;25:111-3.
Inciardi J, Surratt H, Kurtz S, Cicero T. Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Med 2007;8(2):171-83.
Zito J, Safer D, DosReis S, Gardner J, Madger L, Soeken K, et al. Psychotrophic practice patterns for youth: A 10-year perspective. Arch Pediatr Adol Med 2003;157:17-25.
Wong I, Murray M, Camilleri-Novak D, Stephens P. Increased prescribing trends of paediatric psychotrophic medications. Arch Dis Child 2004;89:1131-2.
Wong I, Camilleri-Novak D, Stephens P. Rise in psychotrophic drug prescribing in children in the UK - an urgent public health issue. Drug Saf 2003;26:1117-8.
Mant A, Rendle V, Hall W, Mitchell P, Montgomery W, McManus P, et al. Making new choices about antidepressants in Australia: the long view 1975-2002. Med J Aust 2004;181(7):s21-s4.
Wu L, Pilowsky D, Schlenger W, Galvin D. Misuse of methamphetamine and prescription stimulants among youths and young adults in the community. Drug Alcohol Depend 2007;89:195-205.
Substance Abuse and Mental Health Services Administration. Overview of findings from the 2003 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2004.
International Narcotics Control Board. Report of the International Narcotics Control Board for 2006. New York: United Nations; 2007.
Levine S, Coupey M. Nonmedical use of prescription medications: an emerging risk behaviour among rural adolescents. J Adol Health 2009;44:407-9.
Kelly B, Parsons J. Prescription drug misuse among club drugusing
young adults. Am J Drug Alcohol Abuse 2007;33(6):875-84.
Aldridge J, Measham F. Sildenafil (Viagra) is used as a recreational drug in England. Br Med J 1999;318:669.
Copeland J, Dillon P, Gascoigne M. Ecstasy and the concomitant use of pharmaceuticals. Addict Behav 2006;31:367-70.
Bleeker A, Silins E, Dillon P, Simpson M, Copeland J, Karina H. The feasibility of peer-led interventions to deliver health information to ecstasy and related drug users. NDARC Technical Report No. 299. Sydney: National Drug and Alcohol Research Centre; University of New South Wales; In press.
Gillman P. A review of serotonin toxicity data: Implications for the mechanisms of antidepressant drug action. Biol Psychiatry 2006;59:1046-51.
Silins E, Copeland J, Dillon P. A qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk. Aust N Z J Psychiatry 2007;41(8):649-55.
Swearingen S, Klausner J. Sildenafil use, sexual risk behaviour,
and risk for sexually transmitted diseases, including HIV infection. Am J Med 2005;118:571-7.
Romanelli F, Smith K. Recreational use of sildenafil by HIVpositive
and -negative homosexual/bisexual males. Annals Pharmacotherapy 2004;38:1024-30.
Deehan A, Marshall EStrang J. Tackling alcohol misuse: opportunities and obstacles in priamary care. Br J Gen Pract 1998;48:1779-82.
Roche A. Medical practitioners’ involvement in drug and alcohol
problems: progress and barriers. Subst Abuse 1993;14:106-16.
Sanson-Fisher R, Webb G, Reid A. The role of the medical practitioner as an agent for disease prevention. Better Health Commission: Looking forward to better health 1986;3:201-12.
Stafford J, Sindicich N, Burns L. Australian Drug Trends 2008: Findings from the Illicit Drug Reporting System (IDRS). Australian Drug Trends Series No. 19. Sydney: National Drug and Alcohol Research Centre; University of New South Wales; 2009.
Blum R, Beuhring T, Wunderlich M, Resnick M. Don’t ask, they won’t tell: the quality of adolescent health screening in five practice settings. Am J Public Health 1996;86(12):1767-72.
Friedman P, McCullough D, Saitz R. Screening and intervention for illicit drug abuse. A national survey of primary care physicians and psychiatrists. Arch Intern Med 2001;161:248-51.
Maheux B, Haley N, Rivard M, Gervais A. Do physicians asses lifestyle health risks during general medical examinations? A survey of general practitioners and obstetrician-gynecologists in Quebec. JAMC 1999;160(13):1830-4.
Beck A, Steer R. Beck Anxiety Inventory Manual. San Antonio: Psychological Corporation 1990.
Beck A, Steer R, Brown G. Beck Depression Inventory Manual
(2nd Edition). San Antonio: Psychological Corporation 1996. 37 Keyes K, Martin S, Hasin D. Past 12-month and lifetime comorbidity and polydrug use among young adults in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2008;97:139-49.
Parrott A, Milani R, Parmer R, Turner J. Recreational ecstasy/ MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 2001;159:77-82.
de Win M, Jager G, Vervaeke H, Schilt T, Reneman L, Booij J, et al. The Netherlands XTC Toxicity (NeXT) study: objectives and methods of study investigating causality, course and clinical relevance. Int J Methods Psychiatr Res 2005;14(4):167-85.
Mechan A, Esteban B, O’Shea E, Elliot J, Colado MGreen A. The
pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) to rats. Br J Pharmacol 2002;135:170-80.
Gillman P. Monoamine oxidase inhibitors, opiod analgesics and
serotonin toxicity. Br J Anaesth 2005;95(4):434-41.
Eli Lilly and Company. Prescribing Information: Prozac, fluoxetine hydrochloride [cited 2009 June 14th]; Available from: http://pi.lilly.com/us/prozac.pdf?reqNavId=undefined
Gillman P. Serotonin syndrome: history and risk. Fundam Clin
Pharmacol 1998;12:482-91.
Liechti M, Bauman C, Gamma A, Vollenweider F. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 2000;22(5):513-21.
Vuori E, Henry J, Ojanpera I, Nieminen R, Salovainen T, Wahlsten P, et al. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 2003;98:365-8.
Nandwani R, Gourlay Y. Possible interaction between sildenafil and HIV combination therapy. Lancet 1999;353:840.
Goldmeier D, Lamba H. Prolonged erections produced by dihydrocodeine and sildenafil. Br Med J 2002;324:1555.
Smith K, Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. J Am Pharm Assoc 2005;45(1):63-72.
Alpert J. Viagra: the risks of recreational use. Am J Med 2005;118(6):569-70.
Vollenweider F, Gamma A, Lietchi M, Huber T. Psychological and cardiovascular effects and short-term sequelea of MDMA (‘Ecstasy’) in MDMA-naive healthy volunteers. Neuropsychopharamcology 1998;19:241-51.
Parrott A, Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharamcology 1998;139:261-8.
Parrott A. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharamcology (Berl) 2004;173:234-41.
Tanner-Smith E. Pharmacological content of tablets sold as ‘ecstasy’: Results from an online testing service. Drug Alcohol Depend 2006;83:247-54.
Spruit I. Monitoring synthetic drug markets, trends, and public health. Subst Use Misuse 2001;36(1):23-47.
Green R, Moore D. ‘Kiddie drugs’ and controlled pleasure: Recreational use of dexamphetamine in a social network of young Australians. Int J Drug Policy. In press.
Cunningham J, Sobell L, Chow V. What’s in a label? The effects of substance types and labels on treatment considerations and stigma. J Stud Alcohol 1993;54:693-9.
Link B, Struening E, Rahav M, Phelan J, Nuttbrock L. On stigma and its consequences: evidence from a longitudinal study of men with dual diagnosis of mental illness and substance abuse. J Health Soc Behav 1997;38:177-90.
Kurtz S, Surratt H, Kiley M, Inciardi J. Barriers to health and social services for street-based sex workers. J Health Care Poor Underserved 2005;16:345-61.
Miller N, Sheppard L, Colenda C, Magen J. Why physicians are unprepared to treat patients who have alcohol- and drugrelated disorders. Acad Med 2001;76:410-8.
United Nations Office on Drugs and Crime. Amphetamines and ecstasy: 2008 global ATS assessment. Vienna: United Nations Office on Drugs and Crime; 2008.



